AK104+AK112
Phase 2Biologic
AK104+AK112 is one of 31 biologic programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
251 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Hepsera
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Vermox
WWim Janssens
Preclinical
Statin
Bristol-Myers SquibbPreclinical
AK104+AK112
HHarbin Medical University
Phase 2
Alcohol
AstellasPreclinical
Anti-PD-1 Monoclonal Antibody
IiTeos Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AK104+AK112. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- HHarbin Medical University